Business context and reporting period
American Capital Agency Corp. (AGNC; the company identified in the request as AGNC Investment Corp.) filed this unaudited Form 10-Q for the quarter ended September 30, 2012. It is an externally managed REIT that invests primarily in agency mortgage-backed securities (MBS), financed mainly with short-term repurchase agreements. Unless stated otherwise, financial amounts below are in millions.
Financial performance and position
| Metric | Q3 2012 / September 30, 2012 | Comparable period / date |
|---|---|---|
| Interest income | $520 | $327 in Q3 2011 |
| Net interest income | $381 | $232 in Q3 2011 |
| Net income / common earnings | $86 / $83; $0.25 per common share | $250 / $250; $1.39 per share in Q3 2011 |
| Comprehensive income | $1,327; $3.98 per common share | $274; $1.52 per share in Q3 2011 |
| Common dividends declared | $1.25 per share | $1.40 in Q3 2011 |
| Agency MBS portfolio at fair value | $89,640 | $54,683 at December 31, 2011 |
| Total assets / liabilities | $102,177 / $90,904 | $57,972 / $51,760 at December 31, 2011 |
| Stockholders’ equity / common NAV per share | $11,273 / $32.49 | $6,212 / $27.71 at December 31, 2011 |
| Repurchase agreements and consolidated-VIE debt | $80,262 | $47,735 at December 31, 2011 |
For the nine months ended September 30, 2012, interest income was $1,538, net interest income $1,173, net income $466, and net income available to common shareholders $460 ($1.58 per share). The comparable 2011 amounts were $756, $561, $562, and $562 ($4.19 per share), respectively. Nine-month common dividends declined to $3.75 per share from $4.20.
Q3 2012 net interest spread was 1.42%, compared with 2.14% in Q3 2011; average asset yield fell to 2.55% from 3.14%, while average cost of funds rose to 1.13% from 1.00%. The filing reports Q3 net spread income of $267 ($0.79 per common share), versus $208 ($1.15 per share) a year earlier. Nine-month spread income was $894 ($3.05 per share), versus $510 ($3.80 per share).
For the first nine months, operating cash flow was $1,683, investing cash flow was negative $35,757, and financing cash flow was positive $35,276; cash and cash equivalents increased by $1,202 to $2,569. At September 30, unrestricted cash was $2.6 billion and unpledged agency securities available for liquidity were $4.0 billion. Period-end leverage was approximately 7.0 times equity, net of unsettled trades; average Q3 leverage was 7.1 times.
Material changes versus comparable periods
- Portfolio fair value grew to $89.6 billion from $54.7 billion at year-end 2011, alongside significant common-equity issuance. March and July offerings raised approximately $2.1 billion and $1.2 billion net, respectively; the company also issued $167 million net of Series A preferred stock. Common shares outstanding rose to 341.6 million from 224.1 million at year-end.
- Despite higher net interest income, Q3 net income and common earnings per share fell sharply year over year. The principal reported pressure was a $460 million Q3 loss on derivatives and other securities, compared with a $222 million loss in Q3 2011, along with lower asset yields and a wider cost of funds.
- Q3 other comprehensive income was $1,241, largely reflecting unrealized gains on available-for-sale securities. These gains lifted comprehensive income but are distinct from net income.
- Average asset yield declined and average funding cost increased year over year, compressing the reported spread. The average agency MBS coupon and yield also fell; portfolio yield was 2.61% at September 30, versus 3.07% at December 31, 2011.
- The company expanded its use of repurchase funding and hedging instruments. Repurchase agreements were $79.3 billion, with a 0.46% weighted-average rate and 89 days’ weighted-average remaining maturity at quarter-end. The filing says all margin requirements had been met.
Outlook, commentary, and risks
- Management discussed the Federal Reserve’s September 2012 QE3 announcement: MBS purchases of $40 billion per month, in addition to reinvestment of principal. Management expected total Fed agency-MBS purchases of $65–75 billion monthly and anticipated downward pressure on MBS yields and higher refinancing activity. The filing gives no earnings or dividend guidance.
- Management said 71% of the fixed-rate portfolio was in lower-loan-balance or HARP securities, which it believed had more favorable prepayment characteristics. Its reported portfolio CPR was 9% for Q3; projected life CPR was 14% at quarter-end.
- Interest-rate sensitivity estimates show projected net interest income down 6.5% under a 100-basis-point rate increase and down 19.2% under a 100-basis-point decrease. Estimated NAV changes were negative 3.36% and negative 11.14%, respectively. These are model-based estimates using a static portfolio and stated assumptions; actual results may differ materially.
- Key risks include interest-rate and spread movements, faster or slower mortgage prepayments, extension risk, repo refinancing and margin calls, changing collateral haircuts, liquidity conditions, and counterparty performance. The filing cautions that repo funding may not be renewable on favorable terms or at all.
- At September 30, estimated undistributed 2012 taxable income was $518 million, net of declared common and preferred dividends payable. Management expected to distribute remaining 2012 taxable income during 2012 and 2013, subject to the REIT spill-back provision. The estimate is subject to adjustment.
- In October 2012, the board authorized a discretionary stock-repurchase program of up to $500 million through December 31, 2013. The company said it intended to repurchase only below its estimate of NAV per share; the authorization does not require purchases.
- No material changes to previously disclosed risk factors were reported apart from the new QE3-related risk. The company reported no legal proceedings and said disclosure controls were effective.
Important facts for investors to verify
- Reconcile GAAP net interest income, derivative losses, and non-GAAP net spread income; assess the extent to which reported comprehensive gains depend on unrealized MBS valuations.
- Review MBS premium amortization and prepayment assumptions, including the 14% projected CPR, and sensitivity of asset yields and book value to refinancing activity.
- Assess repo renewal, collateral haircuts, margin-call capacity, counterparty concentration, and the effect of approximately 7-times leverage.
- Examine hedge coverage, derivative valuations and cash costs, including the $536 million deferred swap loss and the expected $194 million reclassification to interest expense over the next 12 months.
- Track taxable-income estimates, dividend coverage, share issuance and dilution, and whether any purchases occur under the authorized buyback program.